Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Abstract Background Anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the therapy of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement. However, its treatment after failure of initial ALK–TKI therapy remains controversial. Case pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Hiroshi Hashimoto, Kazuyuki Komori, Koji Kameda, Shinichi Taguchi, Yuichi Ozeki
Format: Article
Language:English
Published: Japan Surgical Society 2022-04-01
Series:Surgical Case Reports
Subjects:
Anaplastic lymphoma kinase
Tyrosine kinase inhibitor
Lung cancer
Salvage surgery
Alectinib
Lorlatinib
Online Access:https://doi.org/10.1186/s40792-022-01408-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40792-022-01408-7

Similar Items